Elizabeth Redente
Concepts (295)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Fibrosis | 20 | 2026 | 395 | 5.870 |
Why?
| | Idiopathic Pulmonary Fibrosis | 19 | 2026 | 697 | 3.830 |
Why?
| | Fibroblasts | 16 | 2026 | 1034 | 3.730 |
Why?
| | Lung | 31 | 2026 | 4122 | 2.350 |
Why?
| | Bleomycin | 19 | 2026 | 255 | 2.150 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 4 | 2026 | 237 | 2.070 |
Why?
| | Macrophages, Alveolar | 8 | 2025 | 377 | 1.360 |
Why?
| | Indoles | 3 | 2026 | 511 | 1.230 |
Why?
| | Signal Transduction | 13 | 2026 | 5246 | 1.220 |
Why?
| | Apoptosis | 8 | 2026 | 2439 | 1.140 |
Why?
| | Alveolar Epithelial Cells | 8 | 2025 | 121 | 1.030 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 2 | 2026 | 292 | 1.000 |
Why?
| | Mice | 43 | 2026 | 18297 | 0.980 |
Why?
| | Disease Models, Animal | 18 | 2026 | 4580 | 0.900 |
Why?
| | Sulfonamides | 2 | 2026 | 594 | 0.860 |
Why?
| | fas Receptor | 4 | 2020 | 91 | 0.860 |
Why?
| | Animals | 57 | 2026 | 38106 | 0.850 |
Why?
| | Lung Injury | 5 | 2024 | 263 | 0.760 |
Why?
| | Lung Diseases | 4 | 2025 | 787 | 0.750 |
Why?
| | Silicosis | 1 | 2023 | 30 | 0.730 |
Why?
| | Collagen | 5 | 2019 | 460 | 0.670 |
Why?
| | Cytoskeletal Proteins | 1 | 2021 | 146 | 0.650 |
Why?
| | Arthritis, Experimental | 3 | 2018 | 142 | 0.640 |
Why?
| | Transforming Growth Factor beta | 6 | 2020 | 467 | 0.620 |
Why?
| | Monocytes | 5 | 2023 | 538 | 0.620 |
Why?
| | Lung Diseases, Interstitial | 3 | 2023 | 677 | 0.620 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2020 | 117 | 0.580 |
Why?
| | Cell Proliferation | 4 | 2025 | 2502 | 0.580 |
Why?
| | Mice, Inbred C57BL | 17 | 2026 | 6034 | 0.570 |
Why?
| | Respiratory Mucosa | 3 | 2025 | 323 | 0.570 |
Why?
| | Myofibroblasts | 3 | 2026 | 149 | 0.550 |
Why?
| | Cell Separation | 2 | 2019 | 300 | 0.520 |
Why?
| | Macrophages | 9 | 2025 | 1532 | 0.520 |
Why?
| | Lipid Metabolism | 3 | 2026 | 533 | 0.510 |
Why?
| | Epithelial Cells | 4 | 2023 | 1119 | 0.500 |
Why?
| | X-Ray Microtomography | 3 | 2023 | 117 | 0.480 |
Why?
| | Serum Response Factor | 1 | 2015 | 33 | 0.430 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2024 | 1224 | 0.430 |
Why?
| | Wnt Signaling Pathway | 1 | 2017 | 211 | 0.430 |
Why?
| | Mesoderm | 1 | 2015 | 147 | 0.400 |
Why?
| | Flow Cytometry | 4 | 2020 | 1163 | 0.400 |
Why?
| | Actins | 2 | 2026 | 422 | 0.390 |
Why?
| | Cellular Senescence | 2 | 2026 | 225 | 0.380 |
Why?
| | Trans-Activators | 1 | 2015 | 372 | 0.370 |
Why?
| | Pneumonia | 4 | 2023 | 635 | 0.360 |
Why?
| | Cell Polarity | 2 | 2010 | 138 | 0.360 |
Why?
| | Interferon-gamma | 3 | 2010 | 781 | 0.360 |
Why?
| | Lung Neoplasms | 6 | 2018 | 2675 | 0.350 |
Why?
| | Pulmonary Alveoli | 3 | 2025 | 385 | 0.330 |
Why?
| | Disease Progression | 4 | 2025 | 2867 | 0.330 |
Why?
| | Mice, Knockout | 10 | 2020 | 3125 | 0.320 |
Why?
| | Fibrosis | 5 | 2025 | 568 | 0.320 |
Why?
| | Extracellular Matrix | 3 | 2025 | 565 | 0.300 |
Why?
| | Humans | 37 | 2026 | 146342 | 0.300 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 328 | 0.280 |
Why?
| | Cells, Cultured | 9 | 2020 | 4118 | 0.270 |
Why?
| | Adenoma | 2 | 2007 | 210 | 0.270 |
Why?
| | Male | 27 | 2026 | 73396 | 0.260 |
Why?
| | Receptors, Cell Surface | 1 | 2009 | 371 | 0.260 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 2 | 2020 | 22 | 0.260 |
Why?
| | Urethane | 1 | 2007 | 43 | 0.250 |
Why?
| | Carcinogens | 1 | 2007 | 112 | 0.240 |
Why?
| | Macrophage Migration-Inhibitory Factors | 1 | 2025 | 12 | 0.230 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 2025 | 36 | 0.230 |
Why?
| | Lipase | 1 | 2026 | 76 | 0.230 |
Why?
| | Melanoma, Experimental | 2 | 2018 | 106 | 0.230 |
Why?
| | Proteostasis | 1 | 2025 | 32 | 0.230 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2026 | 54 | 0.220 |
Why?
| | Collagen Type I | 1 | 2026 | 144 | 0.220 |
Why?
| | Bone Marrow | 1 | 2007 | 310 | 0.220 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2007 | 314 | 0.210 |
Why?
| | Diet, High-Fat | 1 | 2026 | 267 | 0.210 |
Why?
| | Lung Compliance | 3 | 2014 | 43 | 0.210 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2025 | 365 | 0.200 |
Why?
| | Keratin-8 | 1 | 2023 | 4 | 0.200 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2024 | 16 | 0.200 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2024 | 79 | 0.200 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2024 | 49 | 0.200 |
Why?
| | Fatty Liver | 1 | 2026 | 252 | 0.200 |
Why?
| | Single-Cell Analysis | 3 | 2024 | 370 | 0.200 |
Why?
| | Endoribonucleases | 1 | 2024 | 80 | 0.200 |
Why?
| | Fluorescent Antibody Technique | 2 | 2018 | 345 | 0.200 |
Why?
| | Transcriptome | 3 | 2026 | 1068 | 0.200 |
Why?
| | Intestines | 1 | 2026 | 351 | 0.190 |
Why?
| | Adenocarcinoma | 2 | 2009 | 927 | 0.190 |
Why?
| | Folate Receptor 2 | 1 | 2023 | 8 | 0.190 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2024 | 120 | 0.190 |
Why?
| | Fibroblast Growth Factor 10 | 2 | 2019 | 23 | 0.180 |
Why?
| | Mice, Transgenic | 5 | 2025 | 2134 | 0.180 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2023 | 186 | 0.180 |
Why?
| | Aniline Compounds | 1 | 2023 | 120 | 0.180 |
Why?
| | Membrane Glycoproteins | 1 | 2024 | 495 | 0.180 |
Why?
| | Biomarkers | 3 | 2024 | 4340 | 0.170 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1339 | 0.170 |
Why?
| | Acute Lung Injury | 2 | 2017 | 312 | 0.170 |
Why?
| | Proline | 1 | 2021 | 79 | 0.160 |
Why?
| | Regeneration | 2 | 2019 | 199 | 0.160 |
Why?
| | Neoplasms, Experimental | 1 | 2020 | 163 | 0.150 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2011 | 642 | 0.150 |
Why?
| | Multimodal Imaging | 1 | 2020 | 137 | 0.150 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2019 | 28 | 0.150 |
Why?
| | Interleukin-4 | 2 | 2010 | 207 | 0.150 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 1 | 2018 | 8 | 0.140 |
Why?
| | Gene Deletion | 2 | 2018 | 385 | 0.140 |
Why?
| | Biomedical Research | 1 | 2025 | 729 | 0.140 |
Why?
| | Pulmonary Surfactant-Associated Proteins | 1 | 2018 | 9 | 0.140 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2018 | 19 | 0.130 |
Why?
| | CD11 Antigens | 1 | 2018 | 30 | 0.130 |
Why?
| | Liver | 1 | 2026 | 1864 | 0.130 |
Why?
| | Lipopolysaccharides | 4 | 2024 | 861 | 0.130 |
Why?
| | Adaptive Immunity | 1 | 2018 | 173 | 0.130 |
Why?
| | Macrophage Activation | 2 | 2009 | 182 | 0.130 |
Why?
| | Immunoglobulin M | 1 | 2018 | 284 | 0.130 |
Why?
| | Imaging, Three-Dimensional | 1 | 2021 | 582 | 0.130 |
Why?
| | Antigens, Neoplasm | 1 | 2018 | 271 | 0.120 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2018 | 372 | 0.120 |
Why?
| | Homeostasis | 1 | 2020 | 646 | 0.120 |
Why?
| | Lung Diseases, Fungal | 1 | 2016 | 13 | 0.120 |
Why?
| | Phospholipases A2 | 1 | 2016 | 78 | 0.120 |
Why?
| | Candidiasis | 1 | 2016 | 64 | 0.120 |
Why?
| | Candida albicans | 1 | 2016 | 62 | 0.120 |
Why?
| | CD11b Antigen | 1 | 2016 | 60 | 0.120 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 66 | 0.120 |
Why?
| | Phagocytes | 1 | 2016 | 79 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1792 | 0.110 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2017 | 299 | 0.110 |
Why?
| | Dendritic Cells | 1 | 2018 | 509 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2021 | 1130 | 0.110 |
Why?
| | Stem Cells | 1 | 2019 | 613 | 0.110 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2018 | 931 | 0.100 |
Why?
| | Lipids | 3 | 2024 | 714 | 0.100 |
Why?
| | Mice, Inbred BALB C | 3 | 2016 | 1244 | 0.100 |
Why?
| | Hydroxyproline | 1 | 2014 | 18 | 0.100 |
Why?
| | Receptor, Macrophage Colony-Stimulating Factor | 1 | 2014 | 12 | 0.100 |
Why?
| | Neoplasms | 1 | 2010 | 2954 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 893 | 0.100 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2014 | 25 | 0.100 |
Why?
| | Sex Factors | 3 | 2025 | 2107 | 0.100 |
Why?
| | Arthritis, Rheumatoid | 2 | 2013 | 1185 | 0.100 |
Why?
| | Remission Induction | 1 | 2014 | 308 | 0.100 |
Why?
| | Female | 14 | 2025 | 79499 | 0.100 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2013 | 61 | 0.090 |
Why?
| | Antigens, CD | 1 | 2016 | 560 | 0.090 |
Why?
| | Wound Healing | 2 | 2017 | 354 | 0.090 |
Why?
| | Obesity | 1 | 2026 | 3131 | 0.090 |
Why?
| | Mice, Inbred Strains | 2 | 2010 | 384 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2018 | 1150 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 846 | 0.090 |
Why?
| | Delayed-Action Preparations | 1 | 2012 | 192 | 0.090 |
Why?
| | Leukocytes | 1 | 2013 | 301 | 0.090 |
Why?
| | Cytokines | 5 | 2024 | 2081 | 0.080 |
Why?
| | Chemokine CXCL1 | 1 | 2011 | 76 | 0.080 |
Why?
| | Up-Regulation | 2 | 2011 | 841 | 0.080 |
Why?
| | Trauma Severity Indices | 1 | 2011 | 115 | 0.080 |
Why?
| | Colonic Neoplasms | 1 | 2013 | 259 | 0.080 |
Why?
| | Pyridones | 1 | 2012 | 210 | 0.080 |
Why?
| | Neutrophils | 1 | 2016 | 1133 | 0.080 |
Why?
| | Schistosoma mansoni | 1 | 2010 | 45 | 0.080 |
Why?
| | Butylated Hydroxytoluene | 1 | 2010 | 37 | 0.080 |
Why?
| | Interleukin-4 Receptor alpha Subunit | 1 | 2009 | 9 | 0.080 |
Why?
| | Granuloma | 1 | 2010 | 96 | 0.080 |
Why?
| | Schistosomiasis | 1 | 2010 | 54 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 344 | 0.070 |
Why?
| | Recovery of Function | 1 | 2014 | 725 | 0.070 |
Why?
| | Interleukin-13 | 1 | 2010 | 149 | 0.070 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 197 | 0.070 |
Why?
| | Antigens | 1 | 2011 | 350 | 0.070 |
Why?
| | Testosterone | 1 | 2013 | 419 | 0.070 |
Why?
| | Sex Characteristics | 2 | 2013 | 801 | 0.070 |
Why?
| | Hepatocyte Growth Factor | 2 | 2019 | 33 | 0.070 |
Why?
| | Immunity, Innate | 2 | 2016 | 844 | 0.070 |
Why?
| | Lymph Nodes | 1 | 2011 | 511 | 0.070 |
Why?
| | Societies, Medical | 2 | 2025 | 907 | 0.070 |
Why?
| | Intubation, Intratracheal | 1 | 2011 | 330 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 983 | 0.060 |
Why?
| | Neovascularization, Pathologic | 1 | 2009 | 287 | 0.060 |
Why?
| | Autoimmunity | 1 | 2013 | 925 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 1 | 2009 | 239 | 0.060 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2007 | 162 | 0.060 |
Why?
| | Tuberculosis | 1 | 2010 | 290 | 0.060 |
Why?
| | Cell Line | 3 | 2019 | 2814 | 0.060 |
Why?
| | Survival Rate | 1 | 2011 | 2092 | 0.060 |
Why?
| | Nanoparticles | 1 | 2012 | 523 | 0.060 |
Why?
| | Quinazolines | 1 | 2007 | 267 | 0.060 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2025 | 64 | 0.060 |
Why?
| | Ubiquitin | 1 | 2025 | 84 | 0.060 |
Why?
| | Mast Cells | 1 | 2007 | 150 | 0.060 |
Why?
| | Rats | 3 | 2019 | 5586 | 0.060 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2025 | 155 | 0.050 |
Why?
| | Eye Proteins | 1 | 2024 | 93 | 0.050 |
Why?
| | ErbB Receptors | 1 | 2007 | 636 | 0.050 |
Why?
| | Chronic Disease | 1 | 2010 | 1827 | 0.050 |
Why?
| | Culture Media, Conditioned | 1 | 2024 | 112 | 0.050 |
Why?
| | Age Factors | 1 | 2011 | 3347 | 0.050 |
Why?
| | NADPH Oxidases | 1 | 2024 | 122 | 0.050 |
Why?
| | Time Factors | 1 | 2014 | 7109 | 0.050 |
Why?
| | Wounds and Injuries | 1 | 2010 | 959 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2488 | 0.040 |
Why?
| | Phosphorylation | 2 | 2020 | 1724 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2023 | 2786 | 0.040 |
Why?
| | Photoacoustic Techniques | 1 | 2020 | 5 | 0.040 |
Why?
| | Phenotype | 2 | 2019 | 3206 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3416 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 441 | 0.040 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 104 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1712 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2018 | 2791 | 0.040 |
Why?
| | Research Design | 1 | 2025 | 1143 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2018 | 2599 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 343 | 0.040 |
Why?
| | CD40 Ligand | 1 | 2018 | 32 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2010 | 1957 | 0.040 |
Why?
| | Fibroblast Growth Factor 7 | 1 | 2018 | 15 | 0.030 |
Why?
| | Culture Media, Serum-Free | 1 | 2018 | 42 | 0.030 |
Why?
| | Scleroderma, Systemic | 1 | 2019 | 124 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2019 | 173 | 0.030 |
Why?
| | Pulmonary Surfactants | 1 | 2019 | 105 | 0.030 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 82 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 2018 | 67 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2018 | 161 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2019 | 149 | 0.030 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2018 | 127 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2018 | 183 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2019 | 226 | 0.030 |
Why?
| | Lipogenesis | 1 | 2018 | 62 | 0.030 |
Why?
| | Pilot Projects | 1 | 2023 | 1888 | 0.030 |
Why?
| | Chemokine CXCL12 | 1 | 2017 | 85 | 0.030 |
Why?
| | Reference Values | 1 | 2018 | 796 | 0.030 |
Why?
| | Receptors, CXCR4 | 1 | 2017 | 91 | 0.030 |
Why?
| | Permeability | 1 | 2017 | 166 | 0.030 |
Why?
| | Inflammation | 2 | 2023 | 2919 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2016 | 101 | 0.030 |
Why?
| | Down-Regulation | 1 | 2018 | 614 | 0.030 |
Why?
| | Eicosanoids | 1 | 2016 | 58 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2007 | 2219 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2018 | 633 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 474 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2023 | 1982 | 0.030 |
Why?
| | Organ Specificity | 1 | 2016 | 307 | 0.030 |
Why?
| | United States | 2 | 2025 | 16136 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2018 | 1137 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2017 | 545 | 0.030 |
Why?
| | Smad Proteins | 1 | 2014 | 42 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2016 | 369 | 0.030 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2014 | 54 | 0.030 |
Why?
| | NIH 3T3 Cells | 1 | 2014 | 147 | 0.020 |
Why?
| | Disease Resistance | 1 | 2013 | 30 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2016 | 508 | 0.020 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2013 | 37 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2014 | 275 | 0.020 |
Why?
| | Adenoviridae | 1 | 2014 | 197 | 0.020 |
Why?
| | Polyglactin 910 | 1 | 2012 | 6 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2013 | 238 | 0.020 |
Why?
| | Bronchoalveolar Lavage | 1 | 2012 | 90 | 0.020 |
Why?
| | Tumor Burden | 1 | 2013 | 326 | 0.020 |
Why?
| | Cell Movement | 1 | 2016 | 951 | 0.020 |
Why?
| | Instillation, Drug | 1 | 2011 | 9 | 0.020 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2013 | 227 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2011 | 290 | 0.020 |
Why?
| | Fas Ligand Protein | 1 | 2011 | 61 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1591 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1463 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2011 | 137 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3647 | 0.020 |
Why?
| | Smad3 Protein | 1 | 2010 | 41 | 0.020 |
Why?
| | Smad2 Protein | 1 | 2010 | 37 | 0.020 |
Why?
| | Smoke | 1 | 2011 | 149 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 616 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2009 | 120 | 0.020 |
Why?
| | Tumor Microenvironment | 1 | 2013 | 747 | 0.020 |
Why?
| | Immunoblotting | 1 | 2009 | 294 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2010 | 693 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3926 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1177 | 0.020 |
Why?
| | Injections, Intraperitoneal | 1 | 2007 | 115 | 0.020 |
Why?
| | Erlotinib Hydrochloride | 1 | 2007 | 71 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2010 | 1298 | 0.020 |
Why?
| | Microvessels | 1 | 2009 | 98 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1432 | 0.020 |
Why?
| | Silymarin | 1 | 2009 | 147 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1432 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2009 | 214 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2007 | 250 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 8391 | 0.010 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2010 | 628 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2023 | 17438 | 0.010 |
Why?
| | NF-kappa B | 1 | 2009 | 674 | 0.010 |
Why?
| | Aged | 2 | 2018 | 26432 | 0.010 |
Why?
| | Body Weight | 1 | 2007 | 968 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2011 | 3017 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1761 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2007 | 2022 | 0.010 |
Why?
| | Middle Aged | 2 | 2018 | 36619 | 0.010 |
Why?
| | Prospective Studies | 1 | 2011 | 8123 | 0.010 |
Why?
| | Mutation | 1 | 2007 | 4093 | 0.010 |
Why?
|
|
Redente's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|